Alex Kartvelishvili, MD
Ophthalmology · Iowa City, IANPI 1215124706
Payments from drug & device makers
What this record shows
This record is dominated by ownership interests: $2,403 of the $3,164 with a category attached, or 76.0%. US Retina LLC accounts for 76.0% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2022 at $1,008 and has fallen 72.1% since, to $281 in 2025.
Across 40 payments — averaging $79.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- US Retina LLC$2K
- Regeneron Healthcare Solutions, Inc.$413
- Apellis Pharmaceuticals, Inc.$124
- Bausch & Lomb Americas Inc.$88
- Astellas Pharma US Inc$60
- Genentech USA, Inc.$57
- plus $19 from 1 others
What the payments were for
- Food & beverage$76024%
- Ownership interest$2,40376%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| US Retina LLC | 5 | $2,403 |
| Regeneron Healthcare Solutions, Inc. | 16 | $413 |
| Apellis Pharmaceuticals, Inc. | 8 | $124 |
| Bausch & Lomb Americas Inc. | 4 | $88 |
| Astellas Pharma US Inc | 3 | $60 |
| Genentech USA, Inc. | 3 | $57 |
| Alimera Sciences, Inc. | 1 | $19 |
How this compares
$3,164 in reported general payments places this provider in the 70th percentile of 172 ophthalmology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 191 | $8,880 |
| Atropine Sulfate | 84 | $2,928 |
| Brimonidine Tartrate | 33 | $2,866 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 21 | $2,559 |
| MoxifloxacinMoxifloxacin Hcl | 94 | $1,843 |
| Difluprednate | 12 | $1,441 |
| Ketorolac Tromethamine | 36 | $994 |
| Dorzolamide Hcl | 19 | $431 |
| Timolol Maleate | 38 | $212 |
| Latanoprost | 24 | $196 |
| Prednisone | 20 | $51 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Iowa City
- Michael AbramoffIowa City$158K
- Stephen RussellIowa City$137K
- Alina DumitrescuIowa City$57K
- Keith CarterIowa City$54K
- Erin ShriverIowa City$43K
- James FolkIowa City$34K
- Marc Toeteberg-HarmsIowa City$21K
- Randy KardonIowa City$15K
- Elliott SohnIowa City$7K
- Sohan HayrehIowa City$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.